BioSpace News Archive

According to the report, the global ACL reconstruction procedures market was valued at US$ 6.8 Bn in 2020 and is projected to expand at a moderate CAGR from 2021 to 2031.

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its participation in the following conferences in November.

Sumitomo Dainippon Pharma Oncology, Inc. today announced that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that the Company will participate in the following upcoming virtual investor conferences:

Authorization to conduct INNOVATE Phase 3 trial in India builds on recent regulatory authorizations from Brazil, Philippines, Mexico and Colombia

Apollo Medical Holdings, Inc., a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, announced that the Company’s affiliate has entered into an agreement to purchase within three years all of the remaining equity interests in Diagnostic Medical Group of Southern California.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately.

EpiVax Therapeutics, Inc today announced that an abstract highlighting its Ancer® platform will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting from November 12-14, 2021 in Washington, DC

Pear Therapeutics, Inc., today announced results from an analysis of real-world data evaluating healthcare resource utilization (HCRU) for reSET-O®, the first and only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD).

The 2021 guidelines of the European Society of Cardiology raise the recommendation level for short-term mechanical circulatory support systems such as Impella heart pumps from Class IIb (“may be considered”) to Class IIa (“should be considered”).